<DOC>
	<DOCNO>NCT00107289</DOCNO>
	<brief_summary>The purpose research study find active safe 131 I-MIBG patient resistant neuroblastoma , malignant pheochromocytoma malignant paraganglioma .</brief_summary>
	<brief_title>Iodine I 131 Metaiodobenzylguanidine Treating Patients With Recurrent , Progressive , Refractory Neuroblastoma Malignant Pheochromocytoma Paraganglioma</brief_title>
	<detailed_description />
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Pheochromocytoma</mesh_term>
	<mesh_term>3-Iodobenzylguanidine</mesh_term>
	<criteria>Inclusion criterion NB : Patients must diagnosis NB accordance International Criteria , i.e. , either histopathology ( confirm MSKCC Department Pathology ) BM involvement plus elevated urinary catecholamine . Must history tumor progression recurrence failure achieve complete response standard therapy . Patients must MIBGavid NB evaluable disease MIBG scan time enrollment protocol Prior Therapy : At least 2 week elapse since biologic therapy . Three week elapse since last dose chemotherapy . Age &gt; 1 year determination radiation safety restriction therapy period implement . Stem cell : Patients must autologous hematopoietic stem cell product cryopreserved available reinfusion MIBG treatment . The minimum dose peripheral blood stem cell 2 X106 CD34+ cells/kg . Minimum life expectancy eight week Signed informed consent indicate awareness investigational nature program . Inclusion criterion malignant CCT : Patients must diagnosis malignant CCT i.e . malignant pheochromocytoma malignant paraganglioma Patients must MIBGavid malignant CCT evaluable disease MIBG scan time enrollment protocol Prior Therapy : At least 2 week elapse since biologic therapy . Three week elapse since last dose chemotherapy . Age 1 21 year able cooperate radiation safety restriction therapy period Stem cell : Patients must autologous hematopoietic stem cell product cryopreserved available reinfusion MIBG treatment . The minimum dose peripheral blood stem cell 2 X106 CD34+ cells/kg . Minimum life expectancy eight week . Signed informed consent indicate awareness investigational nature program . Severe major organ toxicity . Specifically , renal , cardiac , hepatic , pulmonary , gastrointestinal neurologic toxicity grade 2 le . A grade 3 hearing deficit acceptable . Active serious infection control antibiotic . Pregnant woman exclude fear danger fetus . Therefore negative pregnancy test require woman childbearing age , appropriate contraception use study period . Inability unwillingness comply radiation safety procedure protocol requirement .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>metastatic pheochromocytoma</keyword>
	<keyword>recurrent pheochromocytoma</keyword>
	<keyword>regional pheochromocytoma</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>04-148</keyword>
</DOC>